Investor Presentaiton
Glaucoma Device Sales in USA and outlook
•
.
US$5.1m (1) sales for the 6 months to
31 December 2023 (65% growth) despite sales in
November and December 2023 negatively impacted by
the uncertainty of proposed reimbursement changes that
were announced on 31 October 2023. Uncertainty
resolved on 29 December 2023 restoring surgeon
purchasing confidence.
Since its USA launch in May 2023 the iTrack™ Advance
has demonstrated a steady increase in demand from
ophthalmologist customers.
With reimbursement uncertainty resolved, Nova Eye
expects USA sales growth to accelerate.
January 2024 sales are up approximately 54% against
January 2023 and in line with December 2023 as
customers are educated on the resolution of the
proposed reimbursement changes and Christmas and
New Year holidays impact purchasing cycles.
USA sales since launch of iTrack TM Advance
Pre reimbursement
uncertainty
During reimbursement
uncertainty
no
Significant month-on-month sales growth post USA
launch of iTrack Advance (74% for the 4 months to 31
October 2023 compared with pcp) (1)
1H FY24 sales up 65% pcp(1)
I
(1) Unaudited sales based on Company financial records
Refer to details in Appendix A
0
Apr-23
May-23 Jun-23
Jul-23
Aug-23 Sep-23 Oct-23
Nov-23 Dec-23
nova-eye.com | 13View entire presentation